Researchers from Carnegie Mellon University have discovered a way to target RNA that could lead to new treatment options for ...
Commercial launch in Switzerland anticipated in H2 2026Pratteln, Switzerland, January 15, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces ...
Researchers from Carnegie Mellon University have discovered a way to target RNA that could lead to new treatment options for myotonic dystrophy type 1 (DM1), the most common adult-onset form of ...
Mary Wickizer, center, shows her son Isaac, 7, the keys to their new wheelchair-accessible van while her husband Matt Wickizer looks on during a special presentation on Nov. 22 at Superior Van & ...
A Sarepta Therapeutics gene therapy that failed its confirmatory test has now converted its accelerated FDA approval into a traditional one, expanding use of the treatment to a wider group of Duchenne ...
US FDA grants Orphan Drug Designation to Atossa Therapeutics’ (Z)-endoxifen to treat Duchenne muscular dystrophy: Seattle Monday, January 19, 2026, 17:00 Hrs [IST] Atossa Therap ...
In research published in Developmental Medicine & Child Neurology, investigators have developed a brief, reliable, and valid ...
Nov. 13 -- THURSDAY, Nov. 12 (HealthDay News) -- Researchers report that a drug used to treat pneumonia might serve as an effective treatment against a type of muscular dystrophy. They tested the drug ...
The muscular dystrophies are commonly associated with cardiovascular complications, including cardiomyopathy and cardiac arrhythmias. These complications are caused by intrinsic defects in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback